Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

被引：0

作者：

Kavgaci, Akif ^{[1
]}

Kula, Serdar ^{[1
]}

Incedere, Fatma ^{[1
]}

Terlemez, Semiha ^{[1
]}

Tunaoglu, Fatma Sedef ^{[1
]}

机构：

[1] Gazi Univ, Fac Med, Dept Pediat, Div Pediat Cardiol, Ankara, Turkiye

来源：

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 2023年 / 31卷 / 01期

关键词：

Pulmonary arterial hypertension; subcutaneous; treprostinil;

D O I：

10.5606/tgkdc.dergisi.2023.23748

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.

引用

页码：145 / 148

页数：4

共 50 条

[1] Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
McSweeney, Julia
Colglazier, Elizabeth
Becerra, Jasmine
Leary, Brienne
Miller-Reed, Kathleen
Walker, Stephen
Tillman, Katy
Magness, Melissa
Ogawa, Michelle
Bannon, Whitney
Kivett, Tisha
Jackson, Emma O. O.
Davis, Anne
Shepard, Cathy
Richards, Susan
Whalen, Elise
Engstrand, Shannon
DiPasquale, Zachary
Connor, Jean A. A.
PULMONARY CIRCULATION, 2023, 13 (02)
[2] Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature
Gavotto, Arthur
Thomas, Fanny
Werner, Oscar
Moreau, Johan
Amedro, Pascal
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 76 (01) : 23 - 31
[3] Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations
Mathier, Michael A.
McDevitt, Susanne
Saggar, Rajan
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (11) : 1210 - 1217
[4] Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil
Ascha, Mona
Zhou, Xuan
Rao, Youlan
Minai, Omar A.
Tonelli, Adriano R.
CARDIOVASCULAR THERAPEUTICS, 2017, 35 (05)
[5] Subcutaneous Treprostinil for Pulmonary Hypertension in Chronic Lung Disease of Infancy
Ferdman, Dina J.
Rosenzweig, Erika B.
Zuckerman, Warren A.
Krishnan, Usha
PEDIATRICS, 2014, 134 (01) : E274 - E278
[6] Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients
Libri, V.
Gibbs, J. S. R.
Pinato, D. J.
Iddamalgoda, T.
Khengar, R. H.
Gin-Sing, W.
Huson, L.
Anand, P.
BRITISH JOURNAL OF ANAESTHESIA, 2014, 112 (02) : 337 - 347
[7] Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Barst, R. J.
Galie, N.
Naeije, R.
Simonneau, G.
Jeffs, R.
Arneson, C.
Rubin, L. J.
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) : 1195 - 1203
[8] Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension
Mouratoglou, Sophia Anastasia
Patsiala, Anthoula
Feloukidis, Christos
Karvounis, Haralambos
Giannakoulas, George
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 187 - 189
[9] Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension
Vachiéry, JL
Hill, N
Zwicke, D
Barst, R
Blackburn, S
Naeije, R
CHEST, 2002, 121 (05) : 1561 - 1565
[10] Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
Lescano, Adrian
Giacommi, Guillermo
Botta, Cristian E.
Soricetti, Julieta
Rodriguez, Manuel
Mielles, Paul Vargas
Diez, Fabian
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16

← 1 2 3 4 5 →